Cn /En

News Center

——

Company news

Industry news

Advantages of InnoModels' ADCC Platform

Author:

InnoModels

Release time:

2024-10-17

InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment:
Precise Targeting to Enhance Therapeutic Effectiveness
The core of the ADCC platform lies in the specific binding of antibodies to the antigens on the surface of tumor cells, which activates the killing effect of immune cells (e.g., NK cells) and achieves a precise strike on tumor cells. This type of targeted therapy has higher selectivity and lower side effects compared with traditional chemotherapy and radiotherapy, and can significantly enhance the treatment effect, bringing better quality of life and longer survival period to patients.
Diversified Experimental Services to Accelerate Drug Development
InnoModels' ADCC platform supports the combination of multiple types of tumor cells and immune cells for experiments, including tumor cell lines, primary tumor cells, genetically engineered cell lines, etc., as well as commercially-sourced and clinically-patient-sourced peripheral blood mononuclear cells (PBMC). This diversified experimental service system provides researchers with a rich choice of space, which can accelerate the development process of new drugs and shorten the translation time of drugs from the laboratory to the clinic.
Efficient Data Processing, Helping Research Decision Making
Equipped with an advanced data analysis system, the platform is capable of automated processing and analysis of experimental data, greatly improving the efficiency and accuracy of data processing. Researchers can intuitively understand the experimental results through the visualization reports provided by the platform, thus better guiding subsequent research work and clinical decision-making. This efficient data processing capability saves researchers a great deal of time and effort, enabling them to focus more on research innovation and exploration.

Customized solutions to meet individual needs
InnoModels' ADCC platform is highly customizable and can be tailored to meet the specific needs of researchers. Whether it is cell type, drug treatment, experiment time or other experimental conditions, the platform can be flexibly adjusted to meet the diverse needs of different researchers. This flexibility gives the platform a unique advantage in personalized research on cancer treatment, and enables it to provide patients with more precise and effective treatment plans.
Promoting Industry-University-Research Cooperation and Technology Transformation
InnoModels Biotechnology has established close partnerships with leading biopharmaceutical companies and research institutions around the world to promote the innovation and application of ADCC technology. Through industry-university-research cooperation, the Company is able to fully utilize the advantages of all parties to accelerate the development and transformation of new technologies, bringing patients more cutting-edge and effective treatments. Meanwhile, the Company also actively participates in academic exchanges and cooperation at home and abroad to promote common progress and development in the field of tumor immunotherapy.
In summary, the ADCC platform of InnoModels Biotechnology has played an important role in promoting the progress of cancer treatment with its advantages of precise targeting, diversified experimental services, efficient data processing, customized solutions and industry-university-research cooperation. In the future, with the continuous development and improvement of the technology, the platform will continue to bring more hope and gospel to cancer patients.

InnoModels Biotechnology ELISpot platform: a powerful tool to precisely analyze the immune response

InnoModels Biotechnology CDC Platform

InnoModels Biotechnology ELISpot platform: a powerful tool to precisely analyze the immune response

InnoModels Biotechnology CDC Platform

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL: +86 15711355061
E-mail: xuyl@imodels.tech
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

InnoModels Biotechnology (Beijing) Co., Ltd

SEO

Business License